Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Ezra E.W. Cohen, Didier Cupissol et al.|The Lancet Oncology|2015Cited by 394
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJ. Guigay, Franck Darloy, Anne Aupérin et al.|The Lancet Oncology|2021Cited by 231
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialPaul M. Clément, Jan B. Vermorken, Thomas Gauler et al.|Annals of Oncology|2016Cited by 45
Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologieB. Guillot, G. Do Outeiro, J. Charles et al.|Annales de Dermatologie et de Vénéréologie|2018Cited by 2